Latest Breaking News On - Eyal shamir - Page 5 : comparemela.com

IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate

IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalJulien frandonEyal shamirTodd kehrliMichael polyviouCompany annual report on formUniversity hospital of montpellierUniversity hospitalCurie institutePrnewswire icecure medical ltdInterventional radiology departmentDisease free survival rateSecondary local controlCure medicalProbe percutaneous cryoablation

IceCure Medical Files Appeal with U S FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer

IceCure Medical Files Appeal with U S FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMichael polyviouTodd kehrliEyal shamirCompany annual report on formPrnewswire icecure medical ltdDrug administrationEuropean unionCompany de novo classificationCure medicalBreakthrough indicationChief executivePrivate securities litigation reform actNovo classificationMiddle eastRisk factors

IceCure Medical Ltd (ICCM) Files Appeal with U S FDA Requesting a Review of its De Novo Classification for ProSense

IceCure Medical Ltd (ICCM) Files Appeal with U S FDA Requesting a Review of its De Novo Classification for ProSense
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Eyal shamirCompany de novo classificationDrug administrationIcecure medical ltdEuropean unionIcecure medicalBreakthrough indicationChief executive

IceCure Medical Files Appeal with U S FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer

IceCure Medical Files Appeal with U S FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer
bubblear.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bubblear.com Daily Mail and Mail on Sunday newspapers.

United statesEyal shamirMichael polyviouTodd kehrliDrug administrationEuropean unionIcecure medical ltdCompany annual report on formCompany de novo classificationIcecure medicalBreakthrough indicationChief executiveCure medicalPrivate securities litigation reform actNovo classificationMiddle east

Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical s ProSense® Cryoablation System

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that in parallel with the growing adoption of ProSense®, the number of independent, non-sponsored studies of its cryoablation system has significantly increased. In addition to the 12 studies already published in peer reviewed journals and presented in scienti

United statesMichael polyviouTodd kehrliEyal shamirIcecure medical ltdCompany annual report on formCure medicalPrivate securities litigation reform actMiddle eastRisk factorsAnnual reportIcecure medical ltdBreast cancerCosmetic resultsMusculoskeletal systemTumor removal